108 related articles for article (PubMed ID: 35705140)
1. Dibutylstannanediyl (2Z,2'Z)-bis(4-(benzylamino)-4-oxobut-2-enoate inhibits prostate cancer progression by activating p38 MAPK/PPARα/SMAD4 signaling.
Waseem D; Khan GM; Haq IU; Syed DN
Toxicol Appl Pharmacol; 2022 Aug; 449():116127. PubMed ID: 35705140
[TBL] [Abstract][Full Text] [Related]
2. The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling.
Waseem D; Khan GM; Haq IU; Rashid U; Syed DN
Toxicol Appl Pharmacol; 2020 Aug; 401():115091. PubMed ID: 32525019
[TBL] [Abstract][Full Text] [Related]
3. Sea cucumber extract TBL-12 inhibits the proliferation, migration, and invasion of human prostate cancer cells through the p38 mitogen-activated protein kinase and intrinsic caspase apoptosis pathway.
Yuan L; Huang X; Zhou K; Zhu X; Huang B; Qiu S; Cao K; Xu L
Prostate; 2019 Jun; 79(8):826-839. PubMed ID: 30889629
[TBL] [Abstract][Full Text] [Related]
4. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].
Zhang YX; Kong CZ
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842
[TBL] [Abstract][Full Text] [Related]
5. Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase 1/2.
Chang HL; Wu YC; Su JH; Yeh YT; Yuan SS
J Pharmacol Exp Ther; 2008 Jun; 325(3):841-9. PubMed ID: 18337475
[TBL] [Abstract][Full Text] [Related]
6. Suppression of cathepsin a inhibits growth, migration, and invasion by inhibiting the p38 MAPK signaling pathway in prostate cancer.
Park S; Kwon W; Park JK; Baek SM; Lee SW; Cho GJ; Ha YS; Lee JN; Kwon TG; Kim MO; Ryoo ZY; Han SH; Han JE; Choi SK
Arch Biochem Biophys; 2020 Jul; 688():108407. PubMed ID: 32407712
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4.
Lan X; Lu G; Yuan C; Mao S; Jiang W; Chen Y; Jin X; Xia Q
J Cancer Res Clin Oncol; 2016 Jan; 142(1):177-85. PubMed ID: 26206483
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of prostate cancer growth by solanine requires the suppression of cell cycle proteins and the activation of ROS/P38 signaling pathway.
Pan B; Zhong W; Deng Z; Lai C; Chu J; Jiao G; Liu J; Zhou Q
Cancer Med; 2016 Nov; 5(11):3214-3222. PubMed ID: 27726305
[TBL] [Abstract][Full Text] [Related]
9. [The role of Smad4 and MAPK proteins in signal transduction pathway in non-small cell lung cancer].
Tong XD; Liu HX; Zhao HR; Xu SG; Li Y; Han LB; Zhang L
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):741-5. PubMed ID: 17366784
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-β/Smad4 signalling pathway by down-regulating DLX1.
Sun B; Fan Y; Yang A; Liang L; Cao J
J Cell Mol Med; 2019 Sep; 23(9):5934-5948. PubMed ID: 31298493
[TBL] [Abstract][Full Text] [Related]
11. A monomer purified from Paris polyphylla (PP-22) triggers S and G2/M phase arrest and apoptosis in human tongue squamous cell carcinoma SCC-15 by activating the p38/cdc25/cdc2 and caspase 8/caspase 3 pathways.
Ke JY; Zhang W; Gong RS; Cen WJ; Huang HQ; Li YR; Kong WD; Jiang JW
Tumour Biol; 2016 Nov; 37(11):14863-14872. PubMed ID: 27644244
[TBL] [Abstract][Full Text] [Related]
12. Involvement of histone H3 phosphorylation through p38 MAPK pathway activation in casticin-induced cytocidal effects against the human promyelocytic cell line HL-60.
Kikuchi H; Yuan B; Yuhara E; Takagi N; Toyoda H
Int J Oncol; 2013 Dec; 43(6):2046-56. PubMed ID: 24064676
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals.
Xie H; Li C; Dang Q; Chang LS; Li L
Oncotarget; 2016 Jan; 7(2):1341-53. PubMed ID: 26625310
[TBL] [Abstract][Full Text] [Related]
14. Berbamine inhibited the growth of prostate cancer cells in vivo and in vitro via triggering intrinsic pathway of apoptosis.
Zhao Y; Lv JJ; Chen J; Jin XB; Wang MW; Su ZH; Wang LY; Zhang HY
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):358-366. PubMed ID: 27431500
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinical significance of the nin one binding protein and p38 MAPK in prostate carcinoma.
Che JP; Li W; Yan Y; Liu M; Wang GC; Li QY; Yang B; Yao XD; Zheng JH
Int J Clin Exp Pathol; 2013; 6(11):2300-11. PubMed ID: 24228091
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of COPS3 inhibits the progress of prostate cancer through reducing phosphorylated p38 MAPK expression and impairs the epithelial-mesenchymal transition process.
Zhu Z; Hong Y; Zhang F; An L; Yang Q; Huang X; Xu Q
Prostate; 2019 Dec; 79(16):1823-1831. PubMed ID: 31509289
[TBL] [Abstract][Full Text] [Related]
17. Effects of salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK.
Zhang B; Wang X; Cai F; Chen W; Loesch U; Bitzer J; Zhong XY
Tumour Biol; 2012 Dec; 33(6):1855-62. PubMed ID: 22773373
[TBL] [Abstract][Full Text] [Related]
18. A novel antitumor piperazine alkyl compound causes apoptosis by inducing RhoB expression via ROS‑mediated c‑Abl/p38 MAPK signaling.
Chung KS; Han G; Kim BK; Kim HM; Yang JS; Ahn J; Lee K; Song KB; Won M
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1315-24. PubMed ID: 24121479
[TBL] [Abstract][Full Text] [Related]
19. Dual specificity phosphatase 1 expression inversely correlates with NF-κB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.
Gil-Araujo B; Toledo Lobo MV; Gutiérrez-Salmerón M; Gutiérrez-Pitalúa J; Ropero S; Angulo JC; Chiloeches A; Lasa M
Mol Oncol; 2014 Feb; 8(1):27-38. PubMed ID: 24080497
[TBL] [Abstract][Full Text] [Related]
20. Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells.
Khwaja FS; Quann EJ; Pattabiraman N; Wynne S; Djakiew D
Mol Cancer Ther; 2008 Nov; 7(11):3539-45. PubMed ID: 18974393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
